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Introduction
The common denominator in CAPS (FCAS, Muckle-
Wells syndrome, NOMID/CINCA) is an uncontrolled
IL-1b release. An often complete response after treatment
with the IL-1 blocker anakinra (Kineret®) has been
demonstrated in all three entities of CAPS [1-3]. However,
the overall documentation is limited due to the inherent
difficulties in conducting randomized studies in the more
severe forms of the disease, and the low prevalence of
CAPS (1 in 1 000 000). The literature consists of uncon-
trolled, small clinical studies, and a large number of case
reports.
Objectives
To estimate CAPS disease activity before and after long-
term treatment with anakinra by a meta-analysis.
Methods
Five major data bases were searched to find published
data on anakinra in the treatment of CAPS. To be
included in the meta-analysis studies had to be prospec-
tively designed and include longitudinal long-term data
(at least 6 month follow-up) on the selected endpoints
and published in a peer reviewed journal. Presence of
primary disease symptoms (rash, headache, arthralgia,
and fever) and on levels of inflammation markers (CRP,
SAA) were selected as endpoints. Pooled estimates were
calculated as weighted average of the individual studies,
using the inverse of variability as weights. The main
meta-analysis was supported by a sensitivity analysis,
conducted by including studies of retrospective nature
and/or providing only short-term data. Data from 5
untreated patients were used as a control group [4].
Results
The search resulted in 14 clinical studies and a large
number of published case reports (n=79) on anakinra
treatment in all CAPS subtypes. Three studies fulfilled
the inclusion studies for the main analysis and three
additional studies for the sensitivity analysis. Selected
studies comprised both pediatric and adult patients in
all three CAPS entities. All four disease symptoms were
present in a large proportion of patients at baseline,
rash being most frequently (95% CI from 83.5% to
97.5%) and fever least frequently reported (95% CI from
46.6% to 71.8%). At the last follow-up visit (11-60
months) the estimated proportion of affected patients was
<20% for each symptom. Almost all patients had abnormal
SAA (95% CI from 85.0 to 98.9% of patients) and CRP
(95% CI from 91.5% to 100.0%) at baseline. Mean SAA
decreased from a baseline value of 41.0 mg/L to 6.9 mg/L
at the last visit and CRP from 28.8 to 6.4 mg/L. Among
the 5 untreated control patients (NOMID/CINCA),
all symptoms except self-reported fever were still present
at the last visit at follow-up (median 52 months). The
sensitivity analyses showed comparable findings.
Conclusion
The results of the present meta-analysis of long-term
efficacy measured as presence of primary disease symp-
toms (rash, headache, arthralgia, and fever) and levels of
inflammation markers (CRP, SAA), confirm the efficacy
of anakinra in the treatment of CAPS, including
NOMID, MWS, and FCAS.
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